What changed for Peripheral Neuropathy
A plain English summary of what recently moved in the public data Voxsanity tracks for Peripheral Neuropathy. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 10 to 11 (+1)
- Trials recruiting worldwide 525 to 539 (+14)
- Trials on record 3,747 to 3,847 (+100)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Peripheral Neuropathy yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 88 trials tracked for Peripheral Neuropathy that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03439046 · results posted 10 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03439046) enrolled 287 participants in its main ("core") phase, where they received a combination of two medicines called ribociclib and letrozole. A smaller group of 21 participants then entered an extension phase and received a different combination — alpelisib and fulvestrant. The trial was primarily measuring how long participants went without their cancer growing or spreading (called "progression-free survival"), and also tracked changes in tumour-related genetic markers found in blood samples over time. The reported...
-
NCT04868123 · results posted 8 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04868123) enrolled 36 people in total — 12 in each of three groups: Mindfulness Meditation, Transcutaneous Nerve Stimulation (TENS, a device that delivers mild electrical pulses through the skin), and Usual Care (the standard treatment people would normally receive). The trial ran for 7 weeks and was measuring two main things: how much pain people felt (pain intensity) and how much that pain got in the way of daily life (pain interference). It also looked at how people walked — including their speed, step length, stride wi...
-
NCT03939481 · results posted 8 June 2026
According to the results reported on ClinicalTrials.gov, this observational study enrolled 1,336 participants who were already receiving chemotherapy as part of their usual care. The study was not testing a new treatment — instead, it was tracking and measuring a common side effect of chemotherapy called peripheral neuropathy (nerve damage that can cause tingling, numbness, or pain, usually in the hands and feet). Participants completed questionnaires and assessments, and 1,114 people completed the study, while 222 did not. The reported data shows that the main thing being measured was how ma...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT07360730 · results posted 30 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 participants, all of whom completed the study with no drop-outs. Every participant received the HPTC Nerve Wrap, a device applied around a damaged nerve. The trial was measuring how well the nerves recovered — both in terms of movement (motor recovery) and feeling (sensory recovery) — as well as pain levels and how well participants were able to use their arms or legs in daily life. The reported data shows that, for movement recovery, 34 out of 40 participants reached a level where the affected muscles could move...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05005845 · results posted 17 February 2026
According to the results reported on ClinicalTrials.gov, this trial involved 199 people in total, split across three groups: 67 people used a vehicle gel (a gel with no active ingredient, sometimes called a placebo), 66 used a 0.5% strength gel called NFX-179, and 66 used a 1.5% strength gel of NFX-179. The trial was looking at skin tumours called cutaneous neurofibromas (small lumps that grow under or on the skin, commonly seen in a condition called neurofibromatosis type 1). The main things being measured were how many participants experienced unwanted medical events after starting treatment...
-
NCT05054725 · results posted 6 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05054725) enrolled 47 people with an advanced or spreading form of lung cancer (non-small cell lung cancer) that carried a specific genetic change called KRASG12C. Participants had already tried standard treatments that had stopped working. The trial tested a combination of two medicines — RMC-4630 and sotorasib — at two different dose levels. The main thing the trial was measuring was the "objective response rate," meaning the proportion of participants whose tumours shrank or disappeared (confirmed by scans taken at leas...
-
NCT05554146 · results posted 13 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05554146) enrolled 34 people in total, split across four groups. Each group received a discount coupon for a different cannabis product: a placebo (no active cannabis), a high-THC product, a product with equal amounts of THC and CBD, or a high-CBD product. The trial ran for 14 weeks and measured self-reported pain levels, certain markers in the blood related to inflammation, and how well participants stuck to their HIV medication (antiretroviral therapy). Between 30 and 34 participants completed the study, with the high-TH...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03962543 · results posted 7 August 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called mirdametinib (also known as PD-0325901) in people with neurofibromatosis type 1 (NF1) who had tumours called plexiform neurofibromas. A total of 114 participants were enrolled — 56 children and 58 adults. The trial's main goal was to measure how many participants had their tumour shrink by at least 20% in volume by the end of the treatment period (up to 24 cycles), as confirmed by independent review of MRI scans. The reported data shows that, among the children's group, approximately 51.8% of parti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05660538 · results posted 1 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05660538) enrolled 194 people in total across four groups: 55 received pregabalin (an existing pain medicine used here for comparison), 28 received a low dose of suzetrigine, 55 received a mid dose of suzetrigine, and 56 received a high dose of suzetrigine. The trial was measuring changes in pain levels over time using an 11-point scale (where 0 means no pain and 10 means the worst imaginable pain), as well as how pain affected sleep, and how participants felt their overall condition had changed. The reported data shows t...
-
NCT05786612 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 102 people in total — 51 in each group. Participants were assigned to have their wounds dressed with either a combination of Mepilex Border and Aquacel Extra Hydrofiber dressings, or Biatain® Silicone dressings. The trial ran for four weeks and was measuring how much wounds shrank in size, as well as how much the dressings cost over that period. The reported data shows that, when wound size at the start of the trial was compared to wound size at four weeks, the Mepilex Border with Aquacel Extra Hydrofiber group had a...
-
NCT04833777 · results posted 10 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 140 people in total — 68 in the lidocaine group and 72 in the bupivacaine group. One person in the lidocaine group did not complete the study, leaving 67 and 72 participants respectively for the final analysis. The trial was comparing two local anaesthetic medicines (lidocaine and bupivacaine) by tracking how much pain participants reported after their operation at multiple points in time following surgery. The reported data shows that pain was measured using a scale from 0 to 10, where 0 means no pain at all and 10...
-
NCT05246670 · results posted 24 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 88 people in total across four groups: 29 received a lower dose of a supplement called PEA (palmitoylethanolamide), 30 received a higher dose of PEA, and 29 received a placebo (an inactive treatment), split across two placebo groups. The trial was measuring whether PEA had any effect on nerve-related symptoms caused by chemotherapy — a condition known as chemotherapy-induced peripheral neuropathy — using a 20-question survey called the CIPN20. On that survey, scores range from 20 to 80, where lower scores mean fewer o...
-
NCT04709419 · results posted 15 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04709419) was set up to compare two types of socks — a "Celliant" sock and a standard control sock — in people with wounds on their feet or legs. The trial aimed to measure three things: changes in the level of oxygen in the tissue around wounds (using a special imaging technique), how many participants achieved complete wound closure, and how many maintained that closure over time. The reported data shows that only one person was enrolled in the Celliant sock group, and no one was enrolled in the control sock group. That...
-
NCT04136184 · results posted 10 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04136184) enrolled 168 people in total — 24 received a medicine called inotersen and 144 received a medicine called eplontersen. The trial was studying a condition involving nerve damage caused by a protein called TTR, and it measured three main things over roughly 65–66 weeks: changes in nerve impairment (using a scoring system called mNIS+7, where a higher score means worse nerve function), changes in quality of life (using a questionnaire called Norfolk QoL-DN, where a higher score means poorer quality of life), and cha...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05139680 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05139680) enrolled 10 participants, all of whom received the medicine tafamidis. All 10 participants completed the study — none dropped out. The trial was looking at whether participants' neurological (nerve-related) function changed over time, comparing a period of at least six months before starting treatment to a period of at least six months after starting treatment. Three different tools were used to measure this: one that assessed muscle weakness (the NIS subscale), one that assessed walking ability (the PND score),...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03860935 · results posted 27 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03860935) enrolled 632 people in total — 421 received acoramidis HCl 800 mg and 211 received a placebo (a dummy pill with no active ingredient). The trial was studying a heart condition called transthyretin amyloid cardiomyopathy, and it tracked four things together over 30 months: deaths from any cause, how often participants were hospitalised for heart-related reasons, changes in a heart-stress blood marker (NT-proBNP), and changes in how far participants could walk in six minutes (the "6-minute walk test"). By the end o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04001829 · results posted 12 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 249 people in total — 126 in Arm A (receiving paclitaxel) and 123 in Arm B (receiving docetaxel). Both paclitaxel and docetaxel belong to a group of chemotherapy medicines called taxanes. The trial was measuring nerve damage in the hands and feet — known as peripheral neuropathy — that can occur as a side effect of these medicines. Participants were also sorted into two groups based on their genetic profile: a "high-risk genotype" group and a "low-risk genotype" group, to see whether a person's genes were linked to ho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02313428 · results posted 25 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02313428) compared two approaches to wound care over 16 weeks. Two participants received standard wound care plus a topical oxygen treatment (where oxygen is applied directly to the wound), and two participants received standard wound care alone. Out of the four people who started the trial, only two — one from each group — completed it fully, meaning the numbers involved are very small. The reported data shows that the main thing being measured was how much wounds closed over 16 weeks, recorded in square centimetres. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05142228 · results posted 22 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05142228) was designed to look at a medication called erenumab-aooe compared to a placebo (an inactive dummy treatment) in people with trigeminal neuropathic pain — a type of ongoing facial nerve pain. The trial aimed to measure things like changes in daily pain scores, the impact of pain on everyday activities such as eating and talking, and effects on anxiety and depression. There were two groups in the study: one receiving erenumab-aooe and one receiving placebo. The reported data shows that only one participant was en...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03952377 · results posted 10 January 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 56 people in total across three groups: 18 received a saltwater injection (used as a placebo-style comparison), 21 received a lower dose of a drug called SX600 (12.5 mg), and 17 received a higher dose of SX600 (25 mg). Most participants completed the study — 16, 19, and 16 respectively across the three groups. The trial was measuring whether SX600, given by injection, could reduce severe leg pain (the kind that can come with back or nerve problems), and it also tracked participants' overall sense of wellbeing, disabil...
-
NCT02510261 · results posted 6 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02510261) enrolled 211 participants across three groups. These were people who had previously taken part in earlier studies of a medicine called patisiran: 49 people who had received a dummy treatment (placebo) in the earlier study, 137 who had received patisiran in that same earlier study, and 25 who had received patisiran in a different earlier study. The trial was measuring things like unwanted medical events that caused people to stop the study, as well as changes over time in nerve damage scores and quality of life sc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03783689 · results posted 29 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03783689) enrolled 38 people in total — 19 in a treatment group and 19 in a control group. The trial was looking at pain after limb amputation, specifically pain in the remaining part of the limb ("residual limb pain") and/or the sensation of pain in the limb that is no longer there ("phantom limb pain"). The main things being measured were how many participants had their pain cut by at least half, and how many experienced a side effect thought to be related to the study. The reported data shows that, for the main pain ou...
-
NCT00220337 · results posted 24 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT00220337) enrolled 371 people who all received the medication lacosamide. There was no comparison group — everyone in the study received the same treatment. Of the 371 who started, 192 completed the trial and 179 did not finish. The trial was primarily designed to monitor and record a range of body measurements and medical events while participants were taking lacosamide, including any untoward medical occurrences, blood test results, and urine test results. The reported data shows that 80.9% of participants experienced a...
-
NCT03267810 · results posted 22 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03267810) enrolled 26 people in total — 13 in each group. Participants were randomly assigned to receive either active TENS (transcutaneous electrical nerve stimulation, a device that delivers mild electrical pulses through the skin) or sham TENS (a dummy version designed to look the same but not deliver the active treatment). The trial was measuring whether participants went on to develop chronic neuropathic pain (persistent nerve pain) after spinal cord injury, and how severe any such pain symptoms were. The reported da...
-
NCT04156802 · results posted 12 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04156802) enrolled 38 people in total across four groups. Participants received one of four types of brain stimulation — either a real or a "sham" (inactive/dummy) version of a technique called Theta Burst Stimulation (TBS), delivered to one of two areas of the brain: the medial prefrontal cortex (mPFC, a region involved in how the brain processes pain) or the motor cortex (MC, a region that controls movement). The trial was measuring whether this type of brain stimulation changed how much pain and discomfort participants...
-
NCT03094832 · results posted 31 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03094832) looked at a medicine called miransertib in people with two rare conditions — PROS (PIK3CA-related overgrowth spectrum) and PS (Proteus syndrome). The trial was run in two parts (Part A and Part B), with Part B divided into several smaller groups, including a compassionate use group for people who needed access outside the main study. In total, 50 people started the trial across all groups. The trial was primarily measuring how many participants experienced any unwanted medical event (called an "adverse event") wh...
-
NCT04051944 · results posted 3 November 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04051944) enrolled 21 adults who received a medicine called rozanolixizumab. Participants were split into two groups: 11 people who were newly starting this treatment, and 10 people who had received it previously as part of an earlier study. The trial was measuring experiences with the treatment, including any unwanted or unexpected medical events (called adverse events) that occurred during or shortly after receiving the medicine. The reported data shows that the primary — that is, the main — thing being tracked was the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03821675 · results posted 9 May 2022
According to the results reported on ClinicalTrials.gov, this trial involved 38 people in total — 19 in an "Active" group who received electrical stimulation therapy, and 19 in a "Sham" group who received a dummy (inactive) version of the treatment. The trial was measuring changes in foot and lower-leg circulation, wound size, foot sensation, and tissue oxygen levels (how much oxygen is getting to the skin) in people with lower-limb wounds. By the end of the trial, 16 people completed the Active group and 17 completed the Sham group, with a small number not finishing in each group. The report...
-
NCT03254394 · results posted 9 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03254394) enrolled 26 people in total — 12 in a group receiving a placebo alongside a chemotherapy regimen called FOLFOX, and 14 in a group receiving lidocaine (a local anaesthetic) alongside the same chemotherapy. The trial was looking at a well-known side effect of one of the chemotherapy drugs (oxaliplatin): a painful sensitivity to cold, as well as longer-term nerve-related symptoms sometimes called chemotherapy-induced peripheral neuropathy (numbness, tingling, or pain in the hands and feet). All participants started...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02722434 · results posted 12 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 50 people in total — 25 in each group. One group received MC5-A Scrambler Therapy (a device that delivers electrical signals to the skin) and the other received TENS Therapy (a more commonly known device that also uses mild electrical pulses on the skin). All participants had nerve-related symptoms — either pain or tingling in their hands or feet — caused by chemotherapy treatment. The main thing the trial was measuring was how many people in each group had at least a 50% reduction in their worst symptom (pain or ting...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 88 reported results for Peripheral Neuropathy
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, peripheral neuropathy attracts a very large amount of public research funding in the United States, and that investment has remained broadly steady year on year. This suggests the condition is viewed as a genuine and ongoing priority by public health researchers, rather than a passing area of interest. For patients, a stable and substantial funding base generally mea...
See the full Peripheral Neuropathy page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.